69 results about "Parathyroid gland" patented technology

The invention discloses a thyroid intraoperative real-time navigation method and a thyroid intraoperative real-time navigation system based on multi-mode optical fusion. The thyroid intraoperative real-time navigation method comprises the following steps: outputting visible light through an endoscope and coupling light waves of a narrow-band multispectral light source to irradiate an operative field, exciting parathyroid glands to generate near-infrared fluorescence, and receiving reflected visible light, split light, near-infrared fluorescence and laser speckle signals through an endoscope probe. And separating the composite optical signal into four channels, and respectively generating an anatomical structure color image, a blood vessel spectroscopic image, a parathyroid gland near-infrared fluorescence image and a laser speckle image. Performing decorrelation processing on the laser speckle image to generate a blood flow dynamic pseudo-color decorrelation speckle image; an anatomical structure, a blood vessel center line, a parathyroid gland contour and blood flow dynamic feature points are extracted through a multi-modal registration technology, after affine transformation space alignment is conducted, a comprehensive imaging map containing the anatomical structure, blood vessel distribution and parathyroid gland function marking information is generated through a wavelet fusion algorithm, and intraoperative multi-dimensional real-time tissue navigation is achieved.

The invention relates to the field of biological medicine, and discloses a pTH long-acting polypeptide compound as well as preparation and application thereof. According to the polypeptide, at least one amino acid residue of the 13th, 26th and 27th amino acid residues of a pTH (1-34) parent peptide sequence is connected with octadecanedioic acid or eicosanoic acid and a derivative modification group of octadecanedioic acid or eicosanoic acid, and the polypeptide is covalently combined with a polypeptide skeleton through an AEA-AEA-gamma-Glu connecting unit. The binding capacity of the polypeptide and serum albumin is remarkably enhanced by utilizing a fatty acid side chain modification means, and meanwhile, the half-life period is prolonged. The pTH long-acting polypeptide compound disclosed by the invention has remarkable osteogenic activity promoting effect, can promote proliferation of MC3T3-E1 cells and generate osteogenic markers and calcium nodules under osteogenic induction conditions, and the binding capacity of the pTH long-acting polypeptide compound and serum albumin is improved by 2-6 times. The invention further provides a solid-phase synthesis method of the polypeptide compound and a pharmaceutical composition containing the polypeptide compound, the polypeptide compound can be used for treating osteoporosis and parathyroid hypofunction, and the compliance problem that an existing medicine needs to be injected every day is effectively solved.

The application discloses a method for detecting small molecules based on an aggregation-induced emission liquid crystal-polymer composite film, and applies the method to the detection of parathyroid hormone. The method introduces TPE-PPE molecules on the basis of traditional liquid crystal detection, prepares luminescent liquid crystals for the detection of substances, and compares the detection results of the fluorescence optical double channel. The optical image can only detect parathyroid hormone above 10 ug / mL, while the sensitivity of the fluorescence to the orientation of the liquid crystal molecules realizes the change of the aggregation state of the AIE, so that the fluorescence detection of the AIE liquid crystal (AIE-LCs) can realize the detection of 1 ng / mL. In addition, 5wt% of the prepolymer is introduced, and ultraviolet irradiation is performed for 8 s. Since the amorphous structure is formed on the surface of the protein, the detection signal is amplified, and the optical and fluorescence detection limits are simultaneously reduced to 0.01 ug / mL and 50 pg / mL respectively.

The application discloses a kind of light illumination methods for laying hens in later egg production stage.The method comprises: in the breeding process of laying hens in later egg production stage, using light source to emit blue light illumination or blue light and white light illumination to irradiate laying hens, so that the illumination can improve eggshell quality.The method of the application can up-regulate the expression of CaBP-D28k gene in eggshell gland of laying hens in later production stage, improve the ability of eggshell calcium deposition, regulate the secretion of parathyroid hormone PTH, calcitonin CT and other hormones, maintain the balance of blood calcium and blood phosphorus, and effectively improve the strength, thickness and weight of eggshell, so as to improve the eggshell quality of eggs produced by laying hens.The application can improve the calcium and phosphorus absorption capacity of laying hens, maintain the balance of calcium and phosphorus metabolism, and has low energy consumption, green energy-saving and environment-friendly advantages.

Provided herein, inter alia, are methods and compositions for treating diabetes mellitus comprising co-transplantation of an insulin-producing cell and a cell derived from a parathyroid gland (PTG), a CD34+ cell derived from a parathyroid gland, a CD34+ cell derived from a stem cell, or other progenitor cell-derived CD34+ cell.

A method and a drug delivery system for transdermally administering parathyroid hormone (PTH) in a pulsatile fashion are provided, where the drug delivery system comprises an array of microprojections each comprising PTH.

Disclosed are compounds that are parathyroid hormone receptor 1 agonists, and methods useful for preventing or treating osteoporosis, fracture, osteomalacia, arthritis, thrombocytopenia, hypoparathyroidism, hyperphosphatemia or tumoral calcinosis.

The invention relates to a livestock breeding technology, and discloses a preparation method of a premix for enhancing laying hen production treatment, in the construction of a basic nutrition framework, the construction of a vitamin system is a core project, vitamin A is supplemented by adopting a palmitate form, the stability of the vitamin A in feed processing is ensured, the level of 8000-12000IU should be maintained in each kilogram of feed, and the content of the vitamin A in the feed processing is reduced. According to the fallopian tube mucous membrane composition, the addition amount of the vitamin D3 in the metabolic activity form of 25-hydroxyD3 needs to reach 2000-3000 IU / kg, the vitamin D3 and parathyroid hormone have a synergistic effect, the calcium and phosphorus deposition efficiency can be remarkably improved, particularly, the synergistic effect of B vitamins is worthy of attention, and thiamine (B1) and riboflavin (B2) are compatible according to the proportion of 1: 2. According to the preparation method of the premix for enhancing laying hen production treatment, the growth speed and the laying efficiency of chicken flocks are effectively improved, the eggshell quality is ensured, nutritional diseases such as chondropathy and egg reduction diseases are reduced, and the economic benefits of laying hen breeding are greatly improved.

Disclosed are compounds that are parathyroid hormone receptor 1 agonists, and methods for the prevention or treatment of osteoporosis, bone fractures, osteomalacia, arthritis, thrombocytopenia, parathyroid hypofunction, hyperphosphatemia, or neoplastic calcaremia.

The invention discloses application of icariin in preparation of drugs for preventing and treating chronic kidney disease mineral substances and bone metabolism disorders. Relates to the technical field of medicine. The invention provides an application of icariin as an active pharmaceutical ingredient in preparation of a CKD-MBD treatment drug. Pharmacological experiments show that icariin can improve renal fibrosis, inhibit hyperparathyroidism, correct calcium and phosphorus metabolism, regulate and control bone metabolism related molecular expression, inhibit transdifferentiation of vascular smooth muscle cells to bone cells, inhibit vascular calcification and correct bone metabolism disorder, so that CKD-MBD is effectively prevented and treated. When icariin is used for preventing or treating CKD-MBD, the icariin is clear in component, exact in curative effect and low in side effect, and has a wide medical application prospect.

A pharmaceutical composition is described herein, which comprises a therapeutically active agent, an absorption enhancer, and a polymer comprising a plurality of alkaline groups. The therapeutically active agent is a parathyroid hormone. A concentration of the polymer in the composition is at least 10 weight percent of the total weight of the composition. The absorption enhancer is preferably a substituted or non-substituted fatty acid or a salt thereof. Further described herein are methods of treating a condition treatable by the therapeutically active agent, comprising orally administering the pharmaceutical composition.

The utility model discloses a kind of parathyroid gland detection devices, belong to medical instrument technical field, including limiting component, installation shell, light guide beam, signal conversion component, light transmission component and connecting lens, installation shell upper end is installed with light guide beam, light guide beam other end is connected with light source, limiting component is installed in installation shell one end, signal transmission cable is installed in limiting component, connecting lens is installed in installation shell other end, light transmission component is installed in installation shell inside, light transmission component one end is opposite connecting lens, light transmission component other end is connected with signal conversion component. Solve the problem that it is easy to be miscut due to the position of parathyroid gland cannot be detected clearly in the prior art. Improve the accuracy of thyroid surgery, prevent the occurrence of complications.

The invention discloses a plasma protein marker for identifying or assisting in identifying parathyroid cancer and parathyroid adenoma and application of the plasma protein marker. The method comprises the following steps: firstly, collecting plasma specimens of a parathyroid carcinoma patient and a parathyroid adenoma patient before an operation, and screening through an unmarked quantitative proteomics technology to obtain 24 differential expression proteins; on the basis of the other part of plasma specimens of the parathyroid carcinoma patient and the parathyroid adenoma patient collected before the operation, the 24 differential expression proteins are verified through a parallel reaction monitoring technology; finally, three plasma protein markers (myoglobin, coronin-1A and a polyimmunoglobulin receptor) which can be used for identifying the parathyroid carcinoma and the parathyroid adenoma are obtained. Experiments prove that the plasma protein marker or the combination thereof can be used for auxiliary differential diagnosis of parathyroid carcinoma and parathyroid adenoma, and has important significance for improving the accuracy of preoperative diagnosis of parathyroid carcinoma.

A parathyroid gland perfusion preservation device is provided, which relates to the field of human organ preservation technologies. The device includes a parathyroid gland preservation box, a perfusion liquid circulation system and a control system. The parathyroid gland preservation box defines a space for placing parathyroid glands. The perfusion liquid circulation system is connected to the parathyroid glands stored in the parathyroid gland preservation box through inlet pipes, indwelling needles and a reflux pipe to supply perfusion liquid to the parathyroid glands. The control system is electrically connected to components of the perfusion liquid circulation system, and configured to receive a working state signal of the components of the perfusion liquid circulation system, and send a control instruction to the components of the perfusion liquid circulation system according to the working state signal. The device can achieve in vitro preservation of parathyroid glands, and can effectively protect the parathyroid glands.

The invention discloses application of a calcimimetic agent in preparation of a medicine for treating autosomal dominant polycystic kidney disease. Pax8rtTA is adopted; tetOCre is taken as a starting material; after a Pkd1fl / fl mouse model is treated by a calcimimetic cinacalcet, by inhibiting secretion of parathyroid hormone, abnormal activation of ciliary positioning Pth1r is reduced, the progress of the polycystic kidney disease is delayed, and the medicine can remarkably delay cyst growth, improve related indexes of renal functions and has a significant clinical application prospect. The abnormal proliferation of cyst epithelial cells and the interstitial fibrosis process of the kidney are effectively inhibited.

The invention discloses a method for rapidly predicting an operation effect in a hyperparathyroidism operation, and belongs to the technical field of medical diagnosis. The invention develops a detection product and designs a novel method for rapidly predicting the surgical effect in hyperparathyroidism surgery, which comprises the following steps: respectively collecting blood samples before and after hyperparathyroidism surgery, and detecting the content of parathyroid hormone in the blood samples by adopting the detection product, obtaining an operation effect prediction result according to the change of the parathyroid hormone content before and after the operation; the detection product contains an anti-parathyroid hormone antibody secreted by a hybridoma cell strain with the preservation number of CCTCC (China Center For Type Culture Collection) No.2025122. According to the invention, the defects of long detection time and harsh sample requirements in the prior art are overcome, the change of the PTH content in the blood sample can be rapidly and accurately detected, whether hyperparathyroid gland excision is complete or not can be judged in an auxiliary manner, the detection time is shortened to 20 minutes, and the operation time is greatly shortened.

This invention belongs to the field of biosensor detection technology, specifically disclosing a carbon dot probe for detecting parathyroid hormone, its preparation method, and its application. The carbon dot probe provided by this invention comprises carbon dots and monoclonal antibodies 1 and 2 covalently coupled to the carbon dot surface. Monoclonal antibodies 1 and 2 specifically recognize the N-terminal and C-terminal epitopes of the parathyroid hormone molecule, respectively. The carbon dots possess aggregation-induced emission (AIE) properties and photosensitivity. This invention's carbon dot probe can achieve a highly sensitive, highly specific, rapid, and dual-mode visual detection method for parathyroid hormone by detecting the dual signal changes of aggregation-induced emission fluorescence enhancement and photocatalytic TMB color development induced by PTH-induced specific aggregation. This invention also provides carbon dots with aggregation-induced emission properties and photosensitivity, as well as a method for preparing the carbon dot probe for detecting parathyroid hormone.

Disclosed are compounds that are parathyroid hormone receptor 1 agonists, and methods useful for preventing or treating osteoporosis, fracture, osteomalacia, arthritis, thrombocytopenia, hypoparathyroidism, hyperphosphatemia or tumoral calcinosis.

A pharmaceutical composition is described herein, which comprises a therapeutically active agent, an absorption enhancer, and a polymer comprising a plurality of alkaline groups. The therapeutically active agent is a parathyroid hormone. A concentration of the polymer in the composition is at least 10 weight percent of the total weight of the composition. The absorption enhancer is preferably a substituted or non-substituted fatty acid or a salt thereof. Further described herein are methods of treating a condition treatable by the therapeutically active agent, comprising orally administering the pharmaceutical composition.

The present invention is based on the realization and verification that inhibition of Luteinizing hormone (LH) and / or luteinizing hormone / choriogonadotropin receptor (LHCGR) is useful in the treatment, alleviation or prevention of different medical states related to perimenopause and menopause in women or hypogonadism in men. Thus, an aspect of the present invention relates to LH and / or LHCGR inhibitors for use in the treatment of postmenopausal osteoporosis in a female subject. Another aspect relates to LH and / or LHCGR inhibitors for use in the reduction of fat mass in a postmenopausal female subject. A further aspect relates to LH and / or LHCGR inhibitors for use in the treatment, hypergonadotropic hypogonadism in a male subject. In addition, another aspect relates to LH and / or LHCGR inhibitors for use in the treatment of symptoms of perimenopause and / or postmenopause such as hot flashes, night sweats, osteoporosis, weight gain, hypothyroidism, conversion of T4 to T3, and / or primary hyperparathyroidism.

The present application belongs to the technical field of kits, and particularly relates to a detachable kit for parathyroid blood supply detection, which comprises a box body, an openable box cover arranged at the top of the box body, a developing solution injection mechanism, a liquid medicine injection mechanism and a three-way connecting mechanism arranged in the box body, a first end of the three-way connecting mechanism being connected with the developing solution injection mechanism, a second end of the three-way connecting mechanism being connected with the liquid medicine injection mechanism, and a third end of the three-way connecting mechanism being used for connecting a remaining needle, the three-way connecting mechanism being capable of being switched between a developing solution injection function and a reagent injection function. The kit designed in the present application is used in cooperation with developing reagents such as indocyanine green aqueous solution, and can guide a doctor to make a decision on whether to retain or transplant parathyroid glands, or help the doctor to find a position of a parathyroid adenoma to be removed during a total thyroidectomy and central lymph node dissection surgery or a parathyroid adenoma resection surgery. The device can be repeatedly used, material is saved, the environment is protected, mechanical injection is achieved, and efficiency is high.

Disclosed are compounds that are parathyroid hormone receptor 1 agonists, and methods useful for preventing or treating osteoporosis, fracture, osteomalacia, arthritis, thrombocytopenia, hypoparathyroidism, hyperphosphatemia or tumoral calcinosis. Also disclosed are agonists of GLP-1R, GCGR, and / or GIPR, and methods of treating various therapeutic indications by administering an effective amount of an agonist of GLP-1R, GCGR, and / or GIPR.

The invention discloses an application of cyclic dipeptide in preparation of drugs for treating diseases related to damage of calcium-sensitive receptors, the dipeptide can directly activate CaSR activity of damaged organ cells in a targeted manner, and can enter the cells to promote expression of CaSR upstream genes, so that the related diseases caused by damage of CaSR are effectively reversed. Animal experiments prove that Cyclo (L-Pro-L-Trp) can effectively improve the symptoms of hypocalcemia, intestinal tract calcium absorption damage, parathyroid hormone excessive secretion, osteoporosis and the like caused by CaSR damage, and non-target organ toxicity is controllable (liver and kidney function indexes are not obviously changed). Cell experiments prove that Cyclo (L-Pro-L-Trp) can effectively activate CaSR of parathyroid gland main cells and intestinal epithelial cells and various calcium ion internal flow channels and promote proliferation of the parathyroid gland main cells and the intestinal epithelial cells.

Embodiments of the present invention disclose a spectrometer-based parathyroid gland identification and blood supply detection device and method. The device comprises an incident optical path, a receiving optical path, and an optical path analysis module. The incident optical path includes a near-infrared light source, a red light source, and an incident optical fiber. The receiving optical path includes a receiving optical fiber, an electrically controlled optical shutter, and a reflected light optical fiber. The optical path analysis module includes a spectrometer and a main control circuit board. The reflected light optical fiber directs light passing through the electrically controlled optical shutter and the receiving optical fiber into the spectrometer. The main control circuit board connects the spectrometer, the electrically controlled optical shutter, the near-infrared light source, and the red light source. The incident optical fiber guides the near-infrared light and red light to a detection target. The receiving optical fiber receives the target's autofluorescence and reflected light. The present invention enables simultaneous parathyroid gland identification and blood supply detection using a single device. It has a simple structure, relatively low cost, and is easily applicable.

The invention relates to the technical field of biological medicine, and provides a dual controlled release compound system of PTH (1-34) and a preparation method and application thereof, the dual controlled release compound system comprises a hydrogel scaffold and PTH (1-34)-loaded microspheres loaded on the hydrogel scaffold; the PTH (1-34) loaded microsphere comprises a microsphere matrix and parathyroid hormone loaded on the microsphere matrix, and the microsphere matrix is composed of a sustained-release polymer. The invention has the following advantages: (1) the PLGA, the HA and the CS have a synergistic effect to form a dual-controlled-release composite scaffold, and the composite scaffold is combined with PTH (1-34) to form a precise controlled-release composite system; the degradation dynamics of the composite scaffold meets the requirement of a bone regeneration time window, and the composite scaffold has high physiological suitability; and (2) a repair system with a three-in-one function of'dual controlled release composite scaffold-microenvironment regulation-anatomical form matching 'is constructed, and has a remarkable curative effect on bone defect repair under pathological load repair.

Disclosed are compounds that are parathyroid hormone receptor 1 agonists, and methods useful for preventing or treating osteoporosis, fracture, osteomalacia, arthritis, thrombocytopenia, hypoparathyroidism, hyperphosphatemia or tumoral calcinosis. Also disclosed are agonists of GLP-1R, GCGR, and / or GIPR, and methods of treating various therapeutic indications by administering an effective amount of an agonist of GLP-1R, GCGR, and / or GIPR.

Disclosed are a compound that is a parathyroid hormone receptor 1 agonist and a method useful for preventing or treating osteoporosis, fractures, osteomalacia, arthritis, thrombocytopenia, hypoparathyroidism, hyperphosphatemia, or neoplastic calcification.

Disclosed are peptide-fatty acid conjugates, pharmaceutical compositions containing them, and methods of their medical use in the treatment of, e.g., a disease or condition associated with the PTHR1 signaling overactivity (e.g., hypercalcemia, hypophosphatemia, hyperparathyroidism, or Jansen's metaphyseal chondrodysplasia) or deficiency (e.g., hypoparathyroidism, hyperphosphatemia, osteoporosis, fracture repair, osteomalacia, arthritis, thrombocytopenia, or chronic kidney disease).

This invention relates to the field of pharmaceutical biotechnology, providing the application of aminoquinoline compounds (such as hydroxychloroquine and chloroquine) in the preparation of drugs for treating hyperparathyroidism. These compounds restore the expression of calcium-sensitive receptors (CaSRs) on the cell membrane surface by inhibiting the lysosomal degradation pathway of CaSRs in parathyroid cells. Experiments have confirmed that 4-aminoquinoline compounds, used alone or in combination with calcimimetics (such as cinacalcet), significantly reduce serum PTH and calcium levels in a model of refractory secondary hyperparathyroidism (SHPT) and inhibit glandular hyperplasia. In particular, the combination therapy regimen exhibits a significant synergistic effect, effectively reversing calcimimetics resistance. This invention is the first to discover a novel use for the antimalarial / antirheumatic drug hydroxychloroquine in the treatment of hyperparathyroidism, realizing a new use for an existing drug; and providing a safe and effective new drug treatment strategy for clinically refractory SHPT.